GoodGut, a CataloniaBio  & HealthTech member, dedicated to early diagnoses to improve digestive health, will now also form part of HIPRA’s  strategy to continue delivering innovative solutions to patients. One of the most innovative products in its portfolio is the RAID-CRC  test, which enables the quick, early and precise detection of colorectal cancer.

The GoodGut company, located at the Science and Technological Park of the University of Girona, was founded by Mariona Serra Pagès, Xavier Aldeguer, Jesús Garcia-Gil and Jaume Amat in 2014 as a spin-off of the University of Girona and the Dr. Josep Trueta Biomedical Research Institute of Girona (IDIBGI). Its focus is on developing  technological solutions based on gut microbiota to enable healthcare systems to achieve precise, reliable and affordable diagnoses and to improve the quality of life for patients with compromised digestive health. After seven years, the biotech company has been able to launch three diagnostic products  onto the market, with presence in more than 79 healthcare sites in Spain, as well as three more products in the works. GoodGut highlight that “this acquisition represents a success for the biotech industry, in which a limited number of start-ups are able to expand and consolidate their projects through mergers or acquisitions. It is an indicator that our entrepreneurial ecosystem is maturing”.

GoodGut’s talent and know-how, along with HIPRA’s experience and capabilities, will enable the development, production and commercialisation of innovative diagnostic tests to detect diseases of the digestive system such as colorectal cancer. It will also allow detection of other inflammatory intestinal diseases like Crohn’s disease, ulcerative colitis or irritable bowel syndrome, a condition that takes between one and five years to detect.